Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Agnieszka Grabowska, PhD

Postdoctoral Scientist


Scientific CV

2010 - 2014
Postdoctoral Scientist, Junior Research Group Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2009 - 2010                       
Postdoctoral Scientist and Project Leader, Okairos / Ceinge - Biotecnologie Avanzate s.c. a r.l., Naples, Italy

Visiting Scientist, Friedrich-Löffler Institute, Federal Research Institute for Animal Health, Institute of Immunology, Tübingen, Germany

2002 - 2009                       
PhD student at the Department of Molecular Virology at the Intercollegiate Faculty of Biotechnology , Gdansk, Poland

1997 - 2002                       
Studies of Biology at the University of Gdansk, Poland

Research Project

Identification of promiscuous HLA class II-restricted human papillomavirus type 16 E2-, E5-, E6- and E7-derived CD4+ helper T cell epitopes for therapeutic vaccine design

Human papillomavirus (HPV)-specific CD4+ T cell responses were found to play a crucial role in the clearance of HPV-induced malignant lesions. Up to now, therapeutic anti-HPV vaccines have mostly been developed to elicit CD8+T cell responses. HPV T cell epitopes have mostly been determined by indirect methods and for the most prevalent HLA-type, HLA-A2. However, the exclusive targeting of HLA class I-restricted HPV epitopes might not be sufficient, since HLA class I alleles may be downregulated in HPV-induced lesions. Therefore, detailed knowledge about naturally processed HLA class II-restricted HPV epitopes could complement future vaccine design strategies.

Resulting Publications

ERAP1 overexpression in HPV-induced malignancies:  a possible novel immune evasion mechanism.
Steinbach A, Winter J, Reuschenbach M, Blatnik R, Klevenz A, Bertrand M, Hoppe S, von Knebel Doeberitz M, Grabowska AK, Riemer AB.
OncoImmunology 2017, 6(7): e1336594.

Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK, Kaufmann AM, Riemer AB.
International Journal of Cancer 2015, 136(1): 212-24.

Therapeutic vaccine strategies against HPV.
Khallouf H, Grabowska AK, Riemer AB.
Vaccines 2014, 2(2): 422-462.

A vaccine targeting mutant IDH1 induces antitumor immunity.
Schumacher T, Bunse L, Sahm F, Pusch S, Quandt J, Wiestler B, Oezen I, Menn O, Osswald M, Grabowska AK, Eichmueller S, Riemer AB, Friese M, Beckhove P, von Deimling A, Wick W, Ott M, Keil M, Balss J, Rauschenbach K, Vogler I, Diekmann J, Sahin U, Stevanovic S, Trautwein N, Okun J, Platten M.
Nature 2014, 512(7514): 324-7.

The invisible enemy – how human papillomaviruses avoid recognition and clearance by the host immune system.
Grabowska AK & Riemer AB.
Open Virology Journal 2012, 6: 249-56.

to top
powered by webEdition CMS